When your care team starts discussing treatment for head and neck cancer, you may hear the term PD-L1, which stands for programmed death-ligand 1. Testing for PD-L1 helps your oncologist determine ...
Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
Hosted on MSN
What is PD-L1, and why does it matter?
When your care team starts discussing treatment for head and neck cancer, you may hear the term PD-L1, which stands for programmed death-ligand 1. Testing for PD-L1 helps your oncologist determine ...
Real-world incidence and clinical outcomes of trastuzumab/pertuzumab-induced thrombocytopenia in adjuvant HER2-positive breast cancer: 8-year retrospective ...
Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...
This retrospective observational study reviewed electronic medical records for all patients with lung cancer diagnosed at King Hussein Cancer Center from January 1, 2017, to April 1, 2024. Included ...
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract PD-L1 biomarker details from an electronic health record (EHR). PD-L1 ...
MedPage Today on MSN
Despite progress in TNBC, more biomarkers are needed to improve outcomes
"PD-L1 is clinically useful but imperfect," expert says ...
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis ...
Agilent Technologies (NYSE:A) secured expanded European approval for its PD-L1 IHC 22C3 pharmDx test for ovarian cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results